325 results on '"Cremon, C"'
Search Results
2. T.12.5: MECHANISTIC ANALYSIS OF FACTORS ASSOCIATED WITH POST COVID-19 IBS OCCURRENCE
3. Collinsella aerofaciens as a predictive marker of response to probiotic treatment in non-constipated irritable bowel syndrome
4. Short-chain fatty acids in IBS: a potentially relevant stratification factor based on catabotyping analysis
5. Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: a potential clinically relevant stratification factor based on catabotyping analysis
6. Colonic immune cells in irritable bowel syndrome: A systematic review and meta‐analysis
7. OC.03.6 GASTROINTESTINAL AUTOIMMUNE DISEASES IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY: A COHORT STUDY
8. T.02.2 GUT EPITHELIAL PERMEABILITY IS ALTERED IN IBS PATIENTS: CORRELATIONS WITH SYMPTOMS AND UNDERLYING MOLECULAR MECHANISMS
9. OC.06.3 POST-COVID-19 IRRITABLE BOWEL SYNDROME
10. Supernatants of irritable bowel syndrome mucosal biopsies impair human colonic smooth muscle contractility
11. Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study
12. Corrigendum: Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier (Front. Nutr., (2021), 8, (718356), 10.3389/fnut.2021.718356)
13. Natural History of Intestinal Failure Induced by Chronic Idiopathic Intestinal Pseudo-Obstruction
14. Neuroimmune interactions in patients with symptomatic uncomplicated diverticular disease
15. Zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome
16. Clinical and Neurochemical Features of chronic constipation in patients with Parkinson disease: PP076**
17. Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS
18. BOC.04.4: THE GUT VASCULAR BARRIER IS IMPAIRED IN IRRITABLE BOWEL SYNDROME: IMPLICATIONS FOR SYMPTOM DEVELOPMENT.
19. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of souble mediators
20. Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry
21. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome
22. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial
23. Gastrointestinal Bleeding In Covid-19 Patients: A Systematic Review And Meta-Analysis
24. Neutral endopeptidase (EC 3.4.24.11) downregulates the onset of intestinal inflammation in the nematode infected mouse
25. A role for inflammation in irritable bowel syndrome? (Visceral Perception)
26. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons
27. Postinfectious Irritable Bowel Syndrome (IBS): Followupat 16 year after a single outbreak of Salmonella gastroenteritis: 005
28. Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders
29. T01.02.5 FOOD AND NON- FOOD ALLERGIES IN DIGESTIVE AND EXTRADIGESTIVE MANIFESTATIONS OF FUNCTIONAL GASTROINTESTINAL DISORDERS
30. T04.02.1 NUTRITIONAL CHARACTERISTICS OF PATIENTS WITH DIVERTICULAR DISEASE: RESULTS FROM THE REMAD REGISTRY
31. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study
32. Idiopathic achalasia is not allelic to alacrima achalasia adrenal insufficiency syndrome at the ALADIN locus
33. Colonic mucosal mast cell mediators of irritable bowel syndrome patients activate sensory nerve pathways in vitro: 145
34. Herpes simplex virus -1 (HSV-1) infection of the enteric nervous system: an in vivo model: 28
35. Excitatory effect of colonic mast cell mediators of irritable bowel syndrome patients on enteric cholinergic motor neurons: 15
36. New pathophysiological mechanisms in irritable bowel syndrome
37. Diagnosis and therapy of irritable bowel syndrome
38. New insights into human enteric neuropathies
39. Role of antibiotic therapy on long-term germ excretion in faeces and digestive symptoms after Salmonella infection
40. P.02.5 THE ROLE OF NEURO-IMMUNE INTERACTIONS AND NERVE SPROUTING IN COLONIC DIVERTICULAR DISEASE
41. P.02.23 DEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH PHARMACOLOGICAL TREATMENTS IN DIVERTICULAR DISEASE: RESULTS FROM THE REMAD REGISTRY
42. P.02.8 USE OF DRUGS PREDISPOSING TO ACUTE DIVERTICULITIS OR BLEEDING IN PATIENTS WITH DIVERTICULAR DISEASE: RESULTS FROM ITALIAN NATIONWIDE REGISTRY (REMAD)
43. Upper gastrointestinal bleeding due to duodenal metastasis from primary lung carcinoma
44. Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators
45. P.05.11 FEATURES OF ABDOMINAL PAIN MAY DISTINGUISH PATIENTS WITH PREVIOUS DIVERTICULITIS FROM PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE: RESULTS FROM THE ITALIAN REGISTRY OF DIVERTICULAR DISEASE (REMAD)
46. P.05.10 DEMOGRAPHIC AND CLINICAL FEATURES DISTINGUISH SUBGROUPS OF DIVERTICULAR DISEASE PATIENTS: RESULTS FROM ITALIAN NATIONWIDE REGISTRY (REMAD)
47. P.05.24 PROGRESSION RATE OF DIVERTICULOSIS AND DIVERTICULAR DISEASE DURING 1 YEAR OF FOLLOW-UP: RESULTS FROM ITALIAN NATIONWIDE REGISTRY (REMAD)
48. Colonic immune cells in irritable bowel syndrome: A systematic review and meta‐analysis
49. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome
50. Irritable bowel syndrome with diarrhea and non-celiac gluten sensitivity are characterized by increased zonulin serum levels
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.